ARS Pharmaceuticals (SPRY) Enterprise Value (2021 - 2025)
ARS Pharmaceuticals (SPRY) has disclosed Enterprise Value for 5 consecutive years, with -$245.0 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 21.98% to -$245.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$245.0 million through Dec 2025, up 21.98% year-over-year, with the annual reading at -$245.0 million for FY2025, 21.98% up from the prior year.
- Enterprise Value hit -$245.0 million in Q4 2025 for ARS Pharmaceuticals, up from -$288.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$60.1 million in Q4 2021 to a low of -$374.2 million in Q1 2021.
- Historically, Enterprise Value has averaged -$257.2 million across 5 years, with a median of -$255.9 million in 2022.
- Biggest YoY gain for Enterprise Value was 32.16% in 2022; the steepest drop was 356.82% in 2022.
- Year by year, Enterprise Value stood at -$60.1 million in 2021, then crashed by 356.82% to -$274.4 million in 2022, then increased by 16.77% to -$228.4 million in 2023, then crashed by 37.51% to -$314.0 million in 2024, then rose by 21.98% to -$245.0 million in 2025.
- Business Quant data shows Enterprise Value for SPRY at -$245.0 million in Q4 2025, -$288.2 million in Q3 2025, and -$240.1 million in Q2 2025.